Jazz Pharmaceuticals plc revenue
Jazz Pharmaceuticals plc's revenue was $4.27bn in fiscal 2025, up 4.9% on the year before. Since fiscal 2009 ($128m) it has grown at a compound 24.5% a year. Over the last twelve months it was $4.72bn.
Revenue history
| Fiscal year | 2009Dec 2009 | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMSept 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 128 | 174 | 272 | 586 | 872 | 1,173 | 1,325 | 1,488 | 1,619 | 1,891 | 2,162 | 2,364 | 3,094 | 3,659 | 3,834 | 4,069 | 4,268 | 4,718 |
| Growth on the year before | — | +35.3% | +56.7% | +115.2% | +48.9% | +34.4% | +13.0% | +12.3% | +8.8% | +16.8% | +14.3% | +9.3% | +30.9% | +18.3% | +4.8% | +6.1% | +4.9% | — |
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Product and Services Product Sales Net of Deductions | $4B | 95.3% | ▲ 5.3% |
| Total Neuroscience (part of Product and Services Product Sales Net of Deductions) | $2.9B | 71.6% | ▲ 6.7% |
| Total Oncology (part of Product and Services Product Sales Net of Deductions) | $1.1B | 28.1% | ▲ 1.6% |
| Defitelio Defibrotide | $199M | 4.7% | ▼ 7.9% |
| Region | Revenue | Share | YoY |
|---|---|---|---|
| United States | $3.8B | 89.8% | ▲ 4.7% |
| Europe | $341M | 8.0% | ▲ 9.1% |
| Other Countries | $94.9M | 2.2% | ▼ 1.3% |
From Jazz Pharmaceuticals plc's 10-K filed February 24, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Jazz Pharmaceuticals plc | $4.72bn | 13.5% | 7.5% |
| Elanco Animal Health Inc | $5.02bn | 12.0% | 5.1% |
| Organon & Co. | $6.10bn | -3.2% | -0.3% |
| Amneal Pharmaceuticals, Inc. | $3.12bn | 9.3% | 10.5% |
| Royalty Pharma plc | $2.54bn | 10.0% | 2.4% |
| Zoetis | $9.52bn | 1.5% | 5.0% |
Compare with peers
- Elanco Animal Health Inc revenue
- Organon & Co. revenue
- Amneal Pharmaceuticals, Inc. revenue
- Royalty Pharma plc revenue
- Zoetis revenue
Head to head: ELAN vs JAZZJAZZ vs OGNAMRX vs JAZZ
More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies